Lung cancer is the leading cause of cancer death worldwide and in the United States. The
majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases
are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains
limited at < 12 months median overall survival. New approaches are needed for second line
chemotherapy treatment. Cabazitaxel-XRP6258 has shown increased overall survival in
metastatic prostate cancer and it is hopeful it can do the same in advanced NSCLC.